Venrock Management VII, LLC 4
4 · Cyteir Therapeutics, Inc. · Filed Jun 23, 2021
Insider Transaction Report
Form 4
Venrock Associates VII, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2021-06-22+3,259,025→ 3,259,025 total(indirect: By Funds) - Conversion
Series C Convertible Preferred Stock
2021-06-22−1,109,368→ 0 total→ Common Stock (325,442 underlying) - Conversion
Series B Convertible Preferred Stock
2021-06-22−10,000,000→ 0 total→ Common Stock (2,933,583 underlying)
Footnotes (2)
- [F1]Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date.
- [F2]Consists of 3,009,710 shares of Common Stock held by Venrock Associates VII, L.P. ("VA VII") and 249,315 shares of Common Stock held by Venrock Partners VII, L.P. ("VP VII"). Venrock Management VII, LLC ("VM VII") is the sole general partner of VA VII and VP VII and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA VII and VP VII except to the extent of its indirect pecuniary interest therein.